Fresenius Group Overview

February 24, 2020

Potentialpark 2020 study shows Fresenius has Germany’s best online offering for job applicants

  • The market research institute Potentialpark has honored the global healthcare group Fresenius as the German company with the best overall Internet offering for job applicants.

    Download Image (JPG 1.54 MB)
Download image

The market research institute Potentialpark has honored the global healthcare group Fresenius for the ninth consecutive year as the German company with the best overall Internet offering for job applicants.

In Potentialpark’s 2020 study, Fresenius not only took first place in the overall category for all career-relevant online activities but won in three of the four individual categories: Online Application Management, Mobile, and Career Website. The company was second in the Social Media category.

Potentialpark has carried out an annual study of German companies’ online offerings for job applicants since 2002. For this year’s study, Potentialpark assessed the online activities of 140 German companies according to more than 300 criteria. More than 46,000 students and graduates around the world were surveyed about their preferences.

“We are delighted to once again receive confirmation of the high quality of our Internet offering for job applicants,” said Michael Lehmann, Senior Vice President Corporate Human Resources of Fresenius. “In the past year we have expanded it with a digital onboarding portal, and are already at work on our next enhancements: We are internationalizing some of our social media channels for potential applicants. And we’re developing a construction kit for the web, so that country units of the Fresenius Group can put together their own career portals, set up to meet their specific requirements.”

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.